PLH-2301
Phase 2Small molecule
PLH-2301 is one of 12 small molecule programs targeting Sarcopenia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Sarcopenia
#DrugCompanyPhaseTrials
1Calciferol
Jazz PharmaceuticalsApproved
Andriol
AAuxilium
Approved
Evrenzo
AstellasPhase 3
Deca-Durabolin
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
TJ0113
HHangzhou PhecdaMed Co., Ltd.
Phase 2
Nexavar
BayerPreclinical
Cialis
Eli LillyPreclinical
Gnrh Agonist
Johnson & JohnsonPreclinical
PLH-2301
PPluto Inc.
Phase 2
Antibiotics
MMelinta Therapeutics, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PLH-2301. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- PPluto Inc.